CEA was initially identified as an antigen highly expressed in CRCs, but subsequent studies have found that it is also expressed in other types of cancers (e.g., breast, lung, pancreatic, and ovarian cancers) and therefore can be used as a tumor biomarker for cancer detection and monitoring [80, 81]. This evidence concerns the gene CEACAM5 and ovarian cancer.